Suppr超能文献

血管内皮因子与慢性肾脏病患者心血管结局及死亡率的关联:一项为期4年的队列研究。

Association of vascular endothelial factors with cardiovascular outcome and mortality in chronic kidney disease patients: a 4-year cohort study.

作者信息

Rambod Mehdi, Heine Gunnar H, Seiler Sarah, Dominic Elizabeth A, Rogacev Kyrill S, Dwivedi Rama, Ramezani Ali, Wing Maria R, Amdur Richard L, Fliser Danilo, Raj Dominic S

机构信息

Department of Internal Medicine, Texas Tech University Health Sciences Center, Paul L. Foster School of Medicine, El Paso, TX, USA.

Saarland University Medical Center and Saarland University Faculty of Medicine, Internal Medicine IV - Nephrology and Hypertension, Homburg, Saar, Germany.

出版信息

Atherosclerosis. 2014 Oct;236(2):360-5. doi: 10.1016/j.atherosclerosis.2014.07.026. Epub 2014 Aug 12.

Abstract

BACKGROUND

Angiogenic cytokines fms-like tyrosine kinase-1(sFlt-1) and placental growth factor (PlGF) are associated with increased risk for cardiovascular disease (CVD) in the general population. In this study we examine the association between these vascular endothelial factors and atherosclerosis, cardiovascular outcome, and mortality in chronic kidney disease (CKD) patients.

METHODS

Serum level of PlGF and sFlt-1 were measured in 301 patients with CKD, who were followed for up to 4 years. Primary outcomes were CV events and all-cause mortality. Carotid-intima media thickness (CIMT) was used as marker of atherosclerosis. Kaplan-Meier survival curves and the Cox proportional hazard model were used to assess the association of biomarkers and clinical outcomes.

RESULTS

Mean (SD) PlGF and sFlt-1 were 5.45 ng/ml (3.76) and 68.6 (28.0) pg/ml, respectively. During the follow up time, 60 patients (19.9%) experienced CV events and 22 patients (7.3%) died. Compared with low PlGF, patients with PlGF above median level had higher CV events (12.7% vs. 27.2%, p = 0.002) and mortality (2.0% vs. 12.6%, p < 0.001). The associations of PlGF and sFlt-1 with CV events were not statistically significant in the fully adjusted model. Higher PlGF was associated with greater death risk (HR = 5.22, 95% CI: 1.49-18.33, p = 0.01), which was robust to adjustment for sFlt-1 and other risk factors. Elevated sFlt-1 level was also an independent predictor of mortality (HR 3.41, 95% CI: 1.49-9.51, p = 0.019).

CONCLUSION

In CKD patients not yet on dialysis, higher serum level of PlGF and sFlt-1 are associated with increased mortality, but not CV events.

摘要

背景

血管生成细胞因子类fms样酪氨酸激酶-1(sFlt-1)和胎盘生长因子(PlGF)与普通人群中心血管疾病(CVD)风险增加相关。在本研究中,我们探讨了这些血管内皮因子与慢性肾脏病(CKD)患者动脉粥样硬化、心血管结局及死亡率之间的关联。

方法

检测了301例CKD患者的血清PlGF和sFlt-1水平,并对其进行了长达4年的随访。主要结局为心血管事件和全因死亡率。颈动脉内膜中层厚度(CIMT)用作动脉粥样硬化的标志物。采用Kaplan-Meier生存曲线和Cox比例风险模型评估生物标志物与临床结局之间的关联。

结果

PlGF和sFlt-1的平均(标准差)水平分别为5.45 ng/ml(3.76)和68.6(28.0)pg/ml。在随访期间,60例患者(19.9%)发生心血管事件,22例患者(7.3%)死亡。与PlGF水平较低的患者相比,PlGF高于中位数水平的患者发生心血管事件的比例更高(12.7%对27.2%,p = 0.002),死亡率也更高(2.0%对12.6%,p < 0.001)。在完全调整模型中,PlGF和sFlt-1与心血管事件之间的关联无统计学意义。较高的PlGF与更高的死亡风险相关(风险比[HR]=5.22,95%置信区间[CI]:1.49 - 18.33,p = 0.01),在对sFlt-1和其他风险因素进行调整后该关联依然显著。sFlt-1水平升高也是死亡率的独立预测因素(HR 3.41,95% CI:1.49 - 9.51,p = 0.019)。

结论

在尚未接受透析的CKD患者中,较高的血清PlGF和sFlt-1水平与死亡率增加相关,但与心血管事件无关。

相似文献

1
Association of vascular endothelial factors with cardiovascular outcome and mortality in chronic kidney disease patients: a 4-year cohort study.
Atherosclerosis. 2014 Oct;236(2):360-5. doi: 10.1016/j.atherosclerosis.2014.07.026. Epub 2014 Aug 12.
2
Vascular endothelial growth factors and risk of cardio-renal events: Results from the CREDENCE trial.
Am Heart J. 2024 May;271:38-47. doi: 10.1016/j.ahj.2024.02.016. Epub 2024 Feb 22.
6
Suppressed soluble Fms-like tyrosine kinase-1 production aggravates atherosclerosis in chronic kidney disease.
Kidney Int. 2014 Feb;85(2):393-403. doi: 10.1038/ki.2013.339. Epub 2013 Sep 18.
7
Association between angiogenic factors and signs of arterial aging in women with pre-eclampsia.
Ultrasound Obstet Gynecol. 2017 Jul;50(1):93-99. doi: 10.1002/uog.15981. Epub 2017 Mar 17.
10
Placental Growth Factor as a Predictor of Cardiovascular Events in Patients with CKD from the NARA-CKD Study.
J Am Soc Nephrol. 2015 Nov;26(11):2871-81. doi: 10.1681/ASN.2014080772. Epub 2015 Mar 18.

引用本文的文献

1
sFlt-1 in Chronic Kidney Disease: Friend or Foe?
Int J Mol Sci. 2022 Nov 16;23(22):14187. doi: 10.3390/ijms232214187.
3
Shrunken Pore Syndrome Is Associated With Increased Levels of Atherosclerosis-Promoting Proteins.
Kidney Int Rep. 2018 Sep 13;4(1):67-79. doi: 10.1016/j.ekir.2018.09.002. eCollection 2019 Jan.
5
Angiogenic Factors and Risks of Technique Failure and Cardiovascular Events in Patients Receiving Peritoneal Dialysis.
Cardiorenal Med. 2016 May;6(3):251-9. doi: 10.1159/000444886. Epub 2016 Mar 31.
6
Placental Growth Factor as a Novel Marker in Uremia-Related Cardiovascular Disease.
Am J Nephrol. 2015;42(2):115-6. doi: 10.1159/000439189. Epub 2015 Sep 15.
7
Placental Growth Factor as a Predictor of Cardiovascular Events in Patients with CKD from the NARA-CKD Study.
J Am Soc Nephrol. 2015 Nov;26(11):2871-81. doi: 10.1681/ASN.2014080772. Epub 2015 Mar 18.

本文引用的文献

1
Associations of FGF-23 and sKlotho with cardiovascular outcomes among patients with CKD stages 2-4.
Clin J Am Soc Nephrol. 2014 Jun 6;9(6):1049-58. doi: 10.2215/CJN.07870713. Epub 2014 Mar 27.
2
Suppressed soluble Fms-like tyrosine kinase-1 production aggravates atherosclerosis in chronic kidney disease.
Kidney Int. 2014 Feb;85(2):393-403. doi: 10.1038/ki.2013.339. Epub 2013 Sep 18.
4
Association between albuminuria, kidney function, and inflammatory biomarker profile in CKD in CRIC.
Clin J Am Soc Nephrol. 2012 Dec;7(12):1938-46. doi: 10.2215/CJN.03500412. Epub 2012 Sep 27.
7
Placental growth factor contributes to bronchial neutrophilic inflammation and edema in allergic asthma.
Am J Respir Cell Mol Biol. 2012 Jun;46(6):781-9. doi: 10.1165/rcmb.2011-0152OC. Epub 2012 Jan 20.
9
Placental growth factor in patients with decreased renal function.
Ren Fail. 2011;33(3):291-7. doi: 10.3109/0886022X.2011.560402.

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验